The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
Abstract
Purpose: TP53 mutations have been described in chronic lymphocytic leukemia (CLL) and have been associated with poor prognosis in retrospective studies. We aimed to address the frequency and prognostic value of TP53 abnormalities in patients with CLL in the context of a prospective randomized trial. Patients and Methods: We analyzed 529 CLL samples from the LRF CLL4 (Leukaemia Research Foundation Chronic Lymphocytic Leukemia 4) trial (chlorambucil v fludarabine with or without cyclophosphamide) at the time of random assignment for mutations in the TP53 gene. TP53 mutation status was correlated with response and survival data. Results: Mutations of TP53 were found in 40 patients (7.6%), including 25 (76%) of 33 with 17p deletion and 13 (3%) of 487 without that deletion. There was no significant correlation between TP53 mutations and age, stage, IGHV gene mutations, CD38 and ZAP-70 expression, or any other chromosomal abnormality other than 17p deletion, in which concordance was high (96%). TP53 mutations were significantly associated with poorer overall response rates (27% v 83%; P < .001) and shorter progression-free survival (PFS) and overall survival (OS; 5-year PFS: 5% v 17%; 5-year OS: 20% v 59%; P < .001 for both). Multivariate analysis that included baseline clinical variables, treatment, and known adverse genetic factors confirmed that TP53 mutations have added prognostic value. Conclusion: TP53 mutations are associated with impaired response and shorter survival in patients with CLL. Analysis of TP53 mutations should be performed in patients with CLL who have progressive disease before starting first-line treatment, and those with mutations should be selected for novel experimental therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999) · Blood · doi:10.1182/blood.v94.6.1848 · Cited by 2,783
Self-citationDamle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., et al. (1999) · Blood · doi:10.1182/blood.v94.6.1840 · Cited by 2,642
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marcé, S., López-Guillermo, A., Campo, E., & Montserrat, E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023143 · Cited by 1,055
Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., et al. (1995) · Blood · doi:10.1182/blood.v85.6.1580.bloodjournal8561580 · Cited by 732
Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M., Bezares, R., Pettitt, A., Hamblin, T., Milligan, D., Child, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61125-8 · Cited by 677
Self-citationTP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Zenz, T., Eichhorst, B., Busch, R., Denzel, T., Häbe, S., Winkler, D., Bühler, A., Edelmann, J., Bergmann, M., Hopfinger, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8762 · Cited by 617
Loehrer, P. J. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79037-7 · Cited by 602
Oscier, D. G., Gardiner, A. C., Mould, S. J., Glide, S., Davis, Z. A., Ibbotson, R. E., Corcoran, M. M., Chapman, R. M., Thomas, P. W., Copplestone, J. A., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1177.h81602001177_1177_1184 · Cited by 522
Self-citationZenz, T., Kröber, A., Scherer, K., Häbe, S., Bühler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwänen, C., et al. (2008) · Blood · doi:10.1182/blood-2008-04-154070 · Cited by 386
Grever, M. R., Lucas, D. M., Dewald, G. W., Neuberg, D. S., Reed, J. C., Kitada, S., Flinn, I. W., Tallman, M. S., Appelbaum, F. R., Larson, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3089 · Cited by 353
Rassenti, L. Z., Jain, S., Keating, M. J., Wierda, W. G., Grever, M. R., Byrd, J. C., Kay, N. E., Brown, J. R., Gribben, J. G., Neuberg, D. S., et al. (2008) · Blood · doi:10.1182/blood-2007-05-092882 · Cited by 326
Rossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gattei, V., Capello, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1630 · Cited by 310
Zenz, T., Häbe, S., Denzel, T., Mohr, J., Winkler, D., Bühler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., et al. (2009) · Blood · doi:10.1182/blood-2009-05-224071 · Cited by 285
Stilgenbauer, S., Zenz, T., Winkler, D., Bühler, A., Schlenk, R. F., Groner, S., Busch, R., Hensel, M., Dührsen, U., Finke, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1128 · Cited by 270
Stilgenbauer, S., Bullinger, L., Lichter, P., Döhner, H., & and the German CLL Study Group (GCLLSG) (2002) · Leukemia · doi:10.1038/sj.leu.2402537 · Cited by 264
Byrd, J. C., Gribben, J. G., Peterson, B. L., Grever, M. R., Lozanski, G., Lucas, D. M., Lampson, B., Larson, R. A., Caligiuri, M. A., & Heerema, N. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1021 · Cited by 257
Dicker, F., Herholz, H., Schnittger, S., Nakao, A., Patten, N., Wu, L., Kern, W., Haferlach, T., & Haferlach, C. (2009) · Leukemia · doi:10.1038/leu.2008.274 · Cited by 208
Malcikova, J., Smardova, J., Rocnova, L., Tichy, B., Kuglik, P., Vranova, V., Cejkova, S., Svitakova, M., Skuhrova Francova, H., Brychtova, Y., et al. (2009) · Blood · doi:10.1182/blood-2009-07-234708 · Cited by 184
Oscier, D. G., Wade, R. L., Davis, Z. A., Morilla, A. M., Best, G., Richards, S. M., Else, M., Matutes, E., & Catovsky, D. (2010) · Haematologica · doi:10.3324/haematol.2010.025338 · Cited by 133
Self-citationTsimberidou, A. M., Tam, C. S. L., Abruzzo, L. V., O'Brien, S. M., Wierda, W. G., Lerner, S. A., Kantarjian, H. M., & Keating, M. J. (2008) · Cancer · doi:10.1002/cncr.23993 · Cited by 114
Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway
Zenz, T., Benner, A., Döhner, H., & Stilgenbauer, S. (2008) · Cell Cycle · doi:10.4161/cc.7.24.7245 · Cited by 85
Gain of Function of p53 Cancer Mutants in Disrupting Critical DNA Damage Response Pathways
Song, H., & Xu, Y. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4456 · Cited by 62
Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia
Zenz, T., Mertens, D., & Stilgenbauer, S. (2010) · Haematologica · doi:10.3324/haematol.2010.027151 · Cited by 13
Cited by
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30262-2 · Cited by 631
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stilgenbauer, S., Schnaiter, A., Paschka, P., Zenz, T., Rossi, M., Döhner, K., Bühler, A., Böttcher, S., Ritgen, M., Kneba, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-546150 · Cited by 516
Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
Xu-Monette, Z. Y., Wu, L., Visco, C., Tai, Y. C., Tzankov, A., Liu, W.-M., Montes-Moreno, S., Dybkær, K., Chiu, A., Orazi, A., et al. (2012) · Blood · doi:10.1182/blood-2012-05-433334 · Cited by 388
Metadata
- Authors
- Gonzalez, D., Martinez, P., Wade, R., Hockley, S., Oscier, D., Matutes, E., Dearden, C. E., Richards, S. M., Catovsky, D., & Morgan, G. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-06-01
- Volume
- 29
- Issue
- 16
- Pages
- 2223-2229
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163923077
- Cited by
- 270
- References
- 25
- FWCI
- 15.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.